open access

Vol 89, No 2 (2021)
Letter to the Editor
Published online: 2021-04-19
Submitted: 2020-11-02
Accepted: 2020-12-12
Get Citation

Timing of Anti-viral therapy in COVID-19: Key to success

Manu Madan, Anant Mohan, Karan Madan, Vijay Hadda, Pawan Tiwari, Randeep Guleria, Saurabh Mittal
DOI: 10.5603/ARM.a2021.0020
·
Pubmed: 33871042
·
Adv Respir Med 2021;89(2):237-239.

open access

Vol 89, No 2 (2021)
LETTERS
Published online: 2021-04-19
Submitted: 2020-11-02
Accepted: 2020-12-12

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Timing of Anti-viral therapy in COVID-19: Key to success

Journal

Advances in Respiratory Medicine

Issue

Vol 89, No 2 (2021)

Article type

Letter to the Editor

Pages

237-239

Published online

2021-04-19

DOI

10.5603/ARM.a2021.0020

Pubmed

33871042

Bibliographic record

Adv Respir Med 2021;89(2):237-239.

Authors

Manu Madan
Anant Mohan
Karan Madan
Vijay Hadda
Pawan Tiwari
Randeep Guleria
Saurabh Mittal

References (12)
  1. Shi X, Lu Y, Li R, et al. Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China. J Med Virol. 2020; 92(10): 1922–1931.
  2. Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020; 64(9).
  3. Madan M, Pahuja S, Mohan A, et al. TB infection and BCG vaccination: are we protected from COVID-19? Public Health. 2020; 185: 91–92.
  4. Galluccio F, Ergonenc T, Martos AG, et al. Treatment algorithm for COVID-19: a multidisciplinary point of view. Clinical Rheumatology. 2020; 39(7): 2077–2084.
  5. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809): 465–469.
  6. Bellingan G, Maksimow M, Howell DC, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med. 2014; 2(2): 98–107.
  7. Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, et al. Interferon-α2b Treatment for COVID-19. Front Immunol 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242746/ (28.09.2020).
  8. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed. https://pubmed.ncbi.nlm.nih.gov/32423584/ (28.09.2020).
  9. Spinner CD, Gottlieb RL, Criner GJ, et al. GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020; 324(11): 1048–1057.
  10. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020; 383(10): 992–993.
  11. Cao B, Zhang D, Wang C, et al. A Trial of lopinavir-ritonavir in Covid-19. N Engl J Med. 2020; 382(21): e68.
  12. Hung IN, Lung KC, Tso EK, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet. 2020; 395(10238): 1695–1704.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl